Alluvi, known as BI 4744, represents a promising advance in obesity care. This dual stimulator targeting both GLP-1 and GIP receptors demonstrates impressive results in clinical studies, potentially outperforming https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/